Cytokine Clinical Trials

By Marta Catalfamo

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) Identifier: NCT05080790 

Contact: Daniel Pink, Dr.              033631 73527  

Contact: Melanie Prause              069 7601 4211

Sponsors and Collaborators

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

EUSA Pharma, Inc.

Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant Identifier: NCT03941769

Contact: Gheath Al-Atrash  713-563-3324

Sponsors and Collaborators

M.D. Anderson Cancer Center

National Cancer Institute (NCI)

Beta Endorphins,Interleukin 1 and Interleukin 38 in Covid Patients Associated With Neuropsychological Manifestations. Identifier: NCT05198388

Contact: somaya redwan younes, master  01099865482

Contact: Eman mosaad zaki, doctor  01065518821

Sponsors and Collaborators

Assiut University

Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo Identifier: NCT05121532


Sohag University

Responsible Party: Samah Saeed Badrous, Sohag University

Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients (INTERCOP)

Principal Investigators: Emanuele Bosi, Professor. IRCCS Ospedale San Raffaele. Milano, Italy, 20132

Contact:  Patrizia Rovere Querini, Professor  Phone: 00390226426768 Identifier: NCT04449380

Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients

Principal Investigators: Brahm H. Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263  

Contact:  Pawel Kalinski, MD, Phone: 716-845-5721 Identifier: NCT04379518

Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis Identifier: NCT03720340

Contact: Yuanyuan Chen, Professor    +86 13738103808

Sponsors and Collaborators

Zhejiang Cancer Hospital           

Hangzhou, Zhejiang, China, 310022

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Identifier: NCT03030378

Principal Investigator:            Diwakar Davar            University of Pittsburgh Cancer Institute LAO

Sponsors and Collaborators

National Cancer Institute (NCI)

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd) Identifier: NCT05049798

Contact: Study Contact            844-434-4210  

Sponsors and Collaborators

Janssen Pharmaceutica N.V., Belgium

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Identifier: NCT05094570

Contact: Kristin W Wavell Shifflett, BS 4349246874

Contact: Deborah Murphy, BSN 4349823510

Sponsors and Collaborators

University of Virginia

Regeneron Pharmaceuticals


Principal Investigator:            Larry C Borish, MD      University of Virginia          

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Identifier: NCT04079088

Contact: US Biogen Clinical Trial Center 866-633-4636           

Contact: Global Biogen Clinical Trial Center           

Sponsors and Collaborators


Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2) Identifier: NCT05070364

Contact: Nicole Ramza, MBA   650-272-6138  

Contact: Monica Gangal, MSc     650-272-6138  

Sponsors and Collaborators

Eiger BioPharmaceuticals

Serum IL 26 as a Marker of Disease Activity in SLE Identifier: NCT05161988

Contact: Fatma Al-zahraa M. Abdel-bary, resident 0201014363853

Contact: Sherif H. Jalal, professor 0201222675000

Sponsors and Collaborators

Assiut University

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Identifier: NCT04979052

Contact: Frank vd Veerdonk, Dr. 0031243618819